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In this study we analyzed selected parameters of apoptosis in leukemic 
cells from peripheral blood and bone marrow of patients with chronic 
lymphocytic leukemia (CLL). The percentage of apoptotic leukemic B 
cells ( mlow/CD19+) was signi  cantly lower in peripheral blood (me-
dian: 0.99%) than in bone marrow (median: 1.41%) (p<0.0001). These 
data can support the idea that these two compartments might have dif-
ferent proliferative statuses. There was an inverse correlation between 
the ex vivo percentage of apoptotic cells and lymphocytosis (R=-0.34; 
p<0.01), and a direct correlation between the percentage of PB apop-
totic B cells and the Rai stage (R=0.42; p<0.05). The percentage of 
mlow/CD19+ cells was signi  cantly higher in ZAP-70-positive patients 
than from ZAP-70-negative patients (p<0.01). There was also a signi  -
cant difference in the median percentage of apoptotic leukemic B cells 
between the patients carrying del(11q22.3) or/and del(17p13.1) (2.7%) 
and the patients without these unfavorable genetic aberrations (1.6%) 
(p<0.01). The B cells from ZAP-70-positive patients with more aggres-
sive disease seem to be more susceptible to spontaneous apoptosis than 
those from ZAP-70-negative patients. We conclude that the evaluation 
of ex vivo apoptosis might provide new important information concer-
ning the biology and prognosis of CLL.
Key words: CLL, ex vivo apoptosis, CMXRos
STRESZCZENIE
W badaniach przeprowadzono analiz  wybranych parametrów apopto-
zy komórek bia aczkowych krwi obwodowej i szpiku chorych na prze-
wlek  bia aczk  limfocytow  (PBL). Odsetek bia aczkowych limfocytów 
B ulegaj cych spontanicznej apoptozie ex vivo ( mlow/CD19+) by  
wi kszy w szpiku (mediana: 1.41%) w porównaniu z krwi  obwodow  
(mediana: 0.99%) (p<0.0001), co mo e sugerowa  zwi zek wi kszej 
apoptozy spontanicznej ze zwi kszon  proliferacj  komórek bia aczko-
wych w szpiku. Stwierdzono ponadto ujemn  korelacj  pomi dzy od-
setkiem komórek apoptotycznych ex vivo a limfocytoz  chorych na PBL 
(R=-0.34; p<0.01) oraz dodatni  korelacj  pomi dzy odsetkiem ko-
mórek apoptotycznych a stadium zaawansowania klinicznego choroby 
(wg Rai’a) (R=0.42; p<0.05). Bia aczkowe limfocyty B z dodatni  eks-
presj  ZAP-70 wydaj  si  by  bardziej podatne na apoptoz  ni  limfo-
cyty B pacjentów ZAP-70-negatywnych (p<0.01). Na uwag  zas uguje 
równie  istotnie wy szy odsetek komórek mlow/CD19+ u pacjentów 
z del(11q22.3) i/lub del(17p13.1) (2.7%) w porównaniu z chorymi bez 
tych niekorzystnych zmian cytogenetycznych (1.6%) (p<0.01). Obser-
wacje te sugeruj , e ocena apoptozy ex vivo mo e dostarczy  nowych 
wa nych informacji dotycz cych biologii i rokowania PBL 
S owa kluczowe: CLL, apoptoza ex vivo, CMXRos
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Introduction
The traditional view has been that chronic lympho-
cytic leukemia (CLL) is a disease deriving from an in-
herent defect in apoptosis pathways, in which slowly 
proliferating B lymphocytes accumulate due to this 
diminished cell death [1]. However, the latest literature 
data suggest that apart from the long-living periphe-
ral blood cells with deregulated apoptosis pathways, 
the population of CLL cells may also contain prolifera-
ting cells originated in the bone marrow, lymph nodes 
or spleen [1–3]. Recent studies suggest that CLL is a 
disease of both proliferation and accumulation [1, 2]. 
Furthermore, it is known that patients with CLL can 
have variable degree of T cells dysfunction. Their ab-
solute number have been reported to be elevated, ho-
wever, the cause for the expansion of various T-cell 
populations in CLL remains unclear. The increase in 
T-cell numbers is mainly due to an increased number 
of CD8+ T cells resulting in an abnormal CD4+/CD8+ 
ratio. Moreover, increasing CD8+ numbers are typi-
cally paralleled by progression of the disease [4].
We investigated a possible relationship between 
apoptosis of leukemic B and T cells and clinical and 
laboratory parameters. We tried to determine whether 
the percentage of apoptotic cells differs between 
patients with better prognostic factors and patients 
with a worse prognosis. Exploring the process of 
apoptosis is of great importance both for understand-
ing this phenomenon and for improving treatment 
options. 
Materials and methods
Patients and samples 
Peripheral blood (PB) and bone marrow (BM) speci-
mens were obtained from 150 newly diagnosed, pre-
viously untreated CLL patients (82 men and 68 wo-
men). The median age was 64 years (ranging from 
32 to 87 years). CLL diagnosis was made on the basis 
of a clinical examination, morphological and immu-
nological criteria [5]. At the time of diagnosis patients 
were staged according to the Rai staging system [6] 
as follows: stage 0 (52 cases), stage 1 (32 cases), stage 
2 (34 cases), stage 3 (17 cases) and stage 4 (15 ca-
ses). The study was approved by the Local Ethical 
Committee. 
Cell Isolation
All PB and BM samples were collected into heparini-
zed tubes and immediately processed. Mononuclear 
cells were separated by density gradient centrifuga-
tion on Biocol (BIOCHROM) for 25 min at 400×g at 
room temperature. Interphase cells were removed, 
washed twice and resuspended in phosphate-buffe-
red saline (PBS).
Determination of apoptosis by Mito Tracker Red 
CMXRos
The level of apoptosis was measured by chloro-
methyl-X-rosamine staining (Mito Tracker Red 
CMXRos; Molecular Probes). CMXRos is a cationic 
lipophilic f luorochrome that does not accumulate in 
depolarized mitochondria and can be used to detect 
disruptions in mitochondrial membrane potential 
(Δ m). CMXRos was used in combination with the 
monoclonal anti-glycophorin A/FITC-conjugated 
antibody (DAKO) to label glycophorin A on the cell 
surface of erythrocytes. It was proved to be useful 
in erythrocyte-contaminated samples with eryth-
rocytes displaying a low Δ m, similar to apoptotic 
cells. CMXRos was also used in combination with 
the monoclonal anti-CD19, anti-CD3, anti-CD4 or 
anti-CD8/ FITC conjugated antibodies (BD Phar-
mingen). Cells were incubated with CMXRos for 30 
min at 37°C and after 15 min of incubation, an-
ti-glycophorin A, anti-CD19, anti CD3, anti-CD4 or 
anti-CD8 MoAbs were added. CD19+, CD3+, CD4+ or 
CD8+ cells considered to be apoptotic displayed a 
decreased in mitochondrial membrane potential in 
CMXRos staining (Δ m low).
Detection of ZAP-70 and CD38 expression 
Flow cytometry analysis of ZAP-70 and CD38 expres-
sion was performed on fresh PB samples, as described 
previously [7]. CLL cells were considered ZAP-70-po-
sitive or CD38-positive when ≥20% of them expressed 
the respective antigen.
I-FISH analysis
Peripheral blood mononuclear cells were cultivated 
for 24 hours in RPMI 1640 medium without mi-
togen stimulation. After hypotonic treatment and 
methanol – acetic acid 3:1 fixation cell suspensions 
were dropped onto microscopic slides and used di-
rectly for I-FISH. The following commercially ava-
ilable Vysis probes (Abbott Molecular Europe) were 
used: LSI ATM SpectrumOrange/CEP 11 Spectrum-
Green Probe and LSI TP53 SpectrumOrange/CEP 
17 SpectrumGreen Probe. At least 200 nuclei were 
analyzed for each probe. The cutoff levels for positi-
ve values determined for normal controls were 2.5% 
(mean ± SD). 
Statistical analysis
The statistical analysis was performed using Sta-
tistica 9.0 PL software. Differences between two 
groups were assessed using the U Mann-Whitney 
test. The Spearman rank correlation coefficient 
was used in correlation tests. The Wilcoxon test 
was used for two dependent variables analyses. 
Differences were considered statistically with 
p-value ≤ 0.05. 
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Fig. 1. The percentage of apoptotic cells in peripheral blood 
(PB) and bone marrow (BM) of untreated CLL patients. 
Ryc. 1. Odsetek komórek apoptotycznych we krwi obwodowej 
oraz szpiku chorych na PBL
Fig. 2. The  ow cytometry dot plots showing the analysis 
of the percentage of apoptotic cells within T CD3+ and B 
CD19+ cell populations.
Ryc. 2. Przyk adowy obraz z cytometru przep ywowego przed-
stawiaj cy odsetek komórek apoptotycznych po ród limfocytów 
T CD3+ i B CD19+
Fig. 3. The percentage of apoptotic cells within T- and B- 
cell populations ( mlow/CD3+and mlow/CD19+) in PB and 
BM of untreated CLL patients. 
Ryc. 3. Odsetek komórek apoptotycznych po ród limfocytów T 
( mlow/CD3+) i B ( mlow/CD19+) we krwi obwodowej i szpiku 
chorych na PBL.
To assess the percentage of apoptotic cells within 
the T-cell and B-cell populations, we performed 
CMXRos staining in combination with the mono-
clonal anti-CD3, anti-CD19, anti-CD8 or anti-CD4/
FITC-conjugated antibodies. Figure 2 shows repre-
sentative plots of Δ mlow/CD19+ and Δ mlow/CD3+ 
cells in PB from CLL patient. In PB, within T-cell pop-
ulation, range of apoptotic cells was 0.11% to 16.93% 
(median: 2.41%). The apoptotic fraction in the B-cell 
population was much lower, with ranges of 0.01% 
to 14.92% (median: 0.94%) (p<0.0001). Likewise, in 
BM the percentage of Δ mlow/CD19+ cells was lower 
(range: 0.05–12.10%; median = 1.25%) than percent-
age of Δ mlow/CD3+ seen within the T-cell population 
(range: 0.09–16.00%; median = 4.00%) (p<0.0001) 
(Figure 3).
Figure 4 shows the results of CMXRos staining of 
CD4+ and CD8+ T-cell subsets in a representative CLL 
patient. Within the CD8+ T-cell subpopulation, the 
range of apoptotic cells was 0.01% to 9.03% (median 
= 1.46%) in PB and 0.01% to 14.01% (median = 2.13%) 
in BM. Within the CD4+ T-cell subpopulation, ranges 
of apoptotic cells were 0.01% to 11.53% (median = 
2.10%) in PB and 0.17% to 17.26% (median = 3.48%) 
in BM. In PB and BM the apoptotic cell fraction within 
CD8+ T-cell population was significantly lower than 
the apoptotic cell fraction within CD4+ T-cell popula-
tion (p<0.01) (Figure 5).
In this study we confirmed, on a larger group 
of patients, our previous observations [8] showing 
inverse correlations between the ex vivo percentage 
of apoptotic cells (Δ mlow/Gly-A) and lymphocytosis 
(R=-0.34; p<0.01). However, we did not observe signif-
icant correlations between the ex vivo percentage of 
apoptotic cells and such prognostic factors as the lac-
Results
We found that the ex vivo percentage of PB apoptotic 
(Δ mlow/Gly-A-) cells in CLL patients (median: 0.99%; 
range: 0.03–9.40%) was significantly lower than that 
of Δ mlow/Gly-A- apoptotic cells in BM samples (me-
dian: 1.41%; range: 0.05–12.5%) p<0.0001) (Figure 1). 
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tate dehydrogenase (LDH) or 2-microglobulin levels. 
We found a direct correlation between the percentage 
of PB apoptotic B cells (Δ mlow/CD19+) and the Rai 
stage (R=0.42; p<0.05). The advanced stage (III-IV) 
patients showed a significantly higher percentage 
of Δ mlow/CD19+ cells (median: 3.13%) than the 0 
(median: 0.77%) or I-II Rai stage patients (median: 
1.11%) (p<0.05) (Figure 6). Furthermore, we detected 
a significantly higher percentage of Δ mlow/CD19+ 
cells in PB and BM from ZAP-70-positive patients 
than from ZAP-70-negative patients (p<0.01). We did 
not show these differences within the T-cell popula-
tion. Likewise, we found no significant differences 
between CD38-positive and CD38-negative patients 
in the analyzed ex vivo apoptosis parameters. 
We analyzed whether the percentage of apoptotic 
cells determined at the time of diagnosis correlated 
with clinical outcome. We found a higher percentage 
of Δ mlow/CD19+ cells in the group of patients requir-
ing treatment (median: 2.60%) than in patients who 
did not (median: 1.72%) (p<0.05). The group of CLL 
patients with a low (<1%) percentage of Δ mlow/CD19+ 
cells had a longer median overall survival (39 months) 
than the group with high percentage of Δ mlow/CD19+ 
cells (32 months), but this difference was not statisti-
cally significant. The ex vivo percentage of apoptotic 
B cells before treatment in CLL patients who died due 
to the progression of the disease was significantly 
higher (median 3.7%) than the percentage of Δ mlow/
CD19+ cells in patients who survived (median 1.2%) 
(p<0.01). We did not show these differences within the 
T-cell population.
Karyotypic analysis at the time of testing was 
available for 52 out of the 150 patients studied. There 
was a significant difference in median percentage of 
Δ mlow/CD19+ cells between the patients carrying 
11q22.3 deletion or/and 17p13.1 deletion (2.7%) and 
the patients without these genetic aberrations (1.6%) 
(p<0.01) (Figure 7). 
Discussion
Apoptosis is a fundamental biological mechanism in-
volved in embryogenesis, morphogenesis and lympho-
Fig. 4. The  ow cytometry dot plots showing the analysis of the percentage of apoptotic cells within CD8+ and CD4+ cell 
populations.
Ryc. 4. Przyk adowy obraz z cytometru przep ywowego przedstawiaj cy odsetek komórek apoptotycznych po ród limfocytów CD8+ i 
CD4+
Fig. 5. The percentage of apoptotic cells within CD8+ and 
CD4+ T cell subpopulations ( mlow/CD8+ and m /CD4+) 
in PB and BM of untreated CLL patients. 
Ryc. 5. Odsetek komórek apoptotycznych po ród limfocytów 
CD8+ i CD4+ ( mlow/CD8+ i mlow/CD4+) we krwi obwodowej 
i szpiku chorych na PBL.
Fig. 6. The percentage of mlow/CD19+ in CLL patients with 
different stages of the disease.
Ryc. 6. Odsetek apoptotycznych komórek mlow/CD19+ u pa-
cjentów w ró nych stadiach zaawansowania PBL.
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id cytotoxicity [9]. The conventional view of CLL has 
been that it is primarily a disease of failed apoptosis 
and passive accumulation [10]. In our study, we used 
CMXRos technique to assess the number of apopto-
tic cells ex vivo in peripheral blood and bone mar-
row of CLL patients. CMXRos technique detects di-
stributions in the mitochondrial membrane potential 
(Δ m), one of the earliest events in the apoptotic path-
way [11,12]. We hypothesised that the assessment of 
ex vivo apoptosis might provide new important infor-
mation regarding the biology and prognosis of CLL. In 
our previous study [8], the ex vivo spontaneous apop-
tosis in CLL patients was significantly lower compa-
red to healthy controls. Low spontaneous apoptosis 
in CLL patients confirmed that defective apoptosis is 
one of the mechanisms of leukemic lymphocyte accu-
mulation. A new finding of the present study was that 
ex vivo spontaneous apoptosis was higher in bone 
marrow than in peripheral blood. Moreover, the per-
centage of apoptotic cells within the T-cell and B-cell 
populations was evaluated. 
Another new finding of our study was that ex vivo 
spontaneous apoptosis of B cells was higher in 
advanced than in early stage patients. The high per-
centage of apoptotic B cells in untreated CLL patients 
with advanced stage is unique and important observa-
tion. Furthermore, we confirmed on a larger group of 
patients our previous data [8] showing inverse correla-
tions between the ex vivo percentage of apoptotic cells 
and lymphocytosis. We can speculate that processes 
other than the accumulation of undying cells might 
also be responsible for a high lymphocyte count in the 
Fig. 7. The percentage of mlow/CD19+ in CLL patients 
subdivided according to cytogenetic analysis. The  rst group 
consisted of the 33 patients having no unfavorable genetic 
aberrations. The second group (n=19) consisted of 12 
patients who had del(11q22.3), 6 patients with del(17p13.1) 
and 1 patients who had simultaneously both aberrations.
Ryc. 7. Odsetek apoptotycznych komórek mlow/CD19+ 
u chorych na PBL w zale no ci od wyst powania zmian cytoge-
netycznych: pierwsza grupa (n=33) - pacjenci bez niekorzystnych 
zmian cytogenetycznych. Druga grupa (n=19): 12 pacjentów 
z del(11q22.3), 6 pacjentów z del(17p13.1) i 1 pacjent z obiema 
aberracjami jednocze nie.
advanced stages of CLL. The previous studies have sug-
gested that proliferation may be an important factor 
contributing to tumor mass growth in CLL. These data 
explain that CLL clone proliferate at appreciable rates 
and cells produced in the bone marrow, lymph nodes 
or spleen may be slowly released into other compart-
ments [1,13,14]. The earlier studies indicate that there 
is an ongoing birth and death within CLL clones, and 
there is an active interaction between these two proc-
esses that determines the numbers of leukemic cells 
[1]. It is likely that proliferating cells show a greater 
ability to enter spontaneous apoptosis.
In these ex vivo studies, we have demonstrated 
that in CLL, the apoptotic fraction was higher within 
the T cells population than within the B-cell popu-
lation. Although the T-cells represent a minority of 
the circulating lymphocytes in CLL, their absolute 
number have been reported to be increased. In addi-
tion both phenotypic and functional abnormalities 
have been described including a decreased CD4:CD8 
ratio, probably resulting from a relative expansion 
of CD8+ T-cell subset [4,15,16]. In our study, in PB 
and BM the apoptotic cell fraction within CD4+ T cells 
was significantly higher than the apoptotic cell frac-
tion within CD8+ T cells. Apoptosis plays an impor-
tant role in regulating the size of the mature T lym-
phocytes, since non-functional and autoreactive T 
cells are eliminated by this process [15]. The results 
of Kiaii et al. [4] demonstrated that T cells, both CD4+ 
and CD8+, in CLL patients could prevent apoptosis of 
leukemic B cells in vitro. Oliveira et al. [17] showed 
the correlations between the CD8 values and the 
clinical and laboratory parameters. They concluded 
that in advanced cases there might be a decreased 
production of CD8 lymphocytes. 
In our study, we tried to assess whether the rate of 
ex vivo apoptosis differs between ZAP-70-positive and 
ZAP-70-negative patients. Interestingly, in the ZAP-70-
-positive group, the percentage of apoptotic cells was 
higher than in the ZAP-70-negative group. One could 
speculate that the higher rate of apoptosis in ZAP-70-
positive patients may be associated with the fact that 
proliferating cells of more advanced cases are more 
prone to apoptosis. This could also explain the higher 
rate of apoptosis in bone marrow than in peripheral 
blood, as bone marrow cells have a higher prolifera-
tion rate than peripheral blood cells. Our result are in 
line with the observations of Coscia et al. [16]. In their 
study leukemic B cells obtained from CLL patients 
with unmutated IgVH showed significantly higher 
rates of in vitro apoptosis as compared with leukemic 
B cells isolated from patients with IgVH mutation.
We also analyzed whether the percentage of apop-
totic cells determined at the time of diagnosis cor-
related with clinical outcome. We found a higher per-
centage of Δ mlow/CD19+ cells in patients requiring 
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treatment than in patients who did not. Patients with 
a high percentage of Δ mlow/CD19+ cells had a shorter 
median overall survival than the patients with a low 
percentage of Δ mlow/CD19+, but this difference was 
not statistically significant. Furthermore, there was a 
higher percentage of apoptotic B cells in patients car-
rying 11q22.3 deletion or/and 17p13.1 deletion than 
in patients without these genetic abnormalities. Our 
findings are in line with the observations of Jahrsdör-
fer et al [18], who have shown more rapid spontane-
ous in vitro apoptosis in patients with poor prognosis 
cytogenetics. They concluded that poor cytogenetics 
in CLL is not associated with a resistance of the cells 
to apoptosis.
In conclusion, our results show that bone marrow 
cells are more sensitive to apoptosis than the cells 
derived from peripheral blood. The present studies 
support the idea that these two compartments have 
different proliferative statuses. The cells from ZAP-70-
-positive patients with more aggressive disease, seem 
to enter apoptosis more rapidly than those from ZAP-
70-negative patients.
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